Clinical Trial Update: A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing adverse events of oral venetoclax with subcutaneous low-dose cytarabine in adult Japanese AML patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: COMPLETED